Galera Therapeutics (GRTX): Company Cash Funds

Galera - graphic logo of issuer GRTX

Galera Therapeutics (GRTX) is experiencing a crisis due to regulatory failures, leading to asset liquidation. The cash position history helps track solvency, with 0.00 representing the latest metric reading. Previously, the business relied on tissue protection during cancer radiation. However, geopolitical tensions and the disruption of reagent logistics are currently blocking the development of new oncology technologies.

GRTX - Galera Therapeutics Company Cash Position over the range 07/04/2022 - 08/04/2024

Analytical breakdowns for Galera Therapeutics (GRTX)

- stock value and consensus price forecast:
- cash availability and cash flow indicators:
Analysis of all company metrics:GRTX Galera Therapeutics
Signature product of Galera

This indicator reflects the net cash balance after all operating and investing expenses. This metric measures actual liquidity, allowing the investor to identify the risk of cash flow gaps. For Galera Therapeutics (GRTX), this is critical, as outsourcing production and trials eliminates capital expenditures but requires constant funding for contracts. By analyzing the cash volume on the balance sheet, one can assess the financial runway of the scientific team.